Climb Bio, Inc. (NASDAQ:CLYM) Receives $15.63 Consensus PT from Analysts

Climb Bio, Inc. (NASDAQ:CLYM) has been assigned an average recommendation of “Buy” from the eleven analysts that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, seven have assigned a buy recommendation and three have assigned a strong buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $15.6250.

A number of research firms have recently weighed in on CLYM. Weiss Ratings reissued a “sell (d-)” rating on shares of Climb Bio in a report on Wednesday, January 21st. Truist Financial began coverage on shares of Climb Bio in a research note on Tuesday, March 17th. They issued a “buy” rating and a $17.00 price target on the stock. Robert W. Baird raised their price target on shares of Climb Bio from $9.00 to $12.00 and gave the stock an “outperform” rating in a research report on Friday, March 6th. HC Wainwright raised their target price on shares of Climb Bio from $11.00 to $15.00 and gave the stock a “buy” rating in a report on Tuesday, March 10th. Finally, Piper Sandler began coverage on Climb Bio in a research report on Friday, February 13th. They set an “overweight” rating on the stock.

Climb Bio Stock Down 6.8%

Climb Bio stock opened at $6.54 on Friday. The company’s 50-day moving average price is $6.10 and its two-hundred day moving average price is $3.85. The stock has a market cap of $312.42 million, a P/E ratio of -7.35 and a beta of -0.26. Climb Bio has a twelve month low of $1.05 and a twelve month high of $8.04.

Climb Bio (NASDAQ:CLYM) last issued its quarterly earnings data on Thursday, March 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.06). Equities analysts anticipate that Climb Bio will post -1.57 earnings per share for the current fiscal year.

Institutional Trading of Climb Bio

Institutional investors have recently modified their holdings of the stock. Blair William & Co. IL acquired a new position in Climb Bio in the fourth quarter valued at about $44,000. Qube Research & Technologies Ltd bought a new position in Climb Bio in the second quarter valued at approximately $43,000. Virtu Financial LLC bought a new position in Climb Bio in the fourth quarter valued at approximately $43,000. AQR Capital Management LLC bought a new position in shares of Climb Bio in the 1st quarter valued at $27,000. Finally, Seven Fleet Capital Management LP bought a new stake in shares of Climb Bio during the 4th quarter worth $306,000. 69.76% of the stock is currently owned by institutional investors.

Climb Bio Company Profile

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.